Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis


Published in:
Annals of the Rheumatic Diseases

DOI:
10.1136/ard.2010.144998

Citation for published version (APA):
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

Maya H Buch,¹,² Josef S Smolen,³,⁴ Neil Betteridge,⁵ Ferdinand C Bredveld,⁶ Gerd Burmester,⁷ Thomas Dörner,⁷ Gianfranco Ferraccioli,⁸ Jacques-Eric Gottenberg,⁹ John Isaacs,¹⁰ Tore K Kvien,¹¹ Xavier Mariette,¹² Emilio Martin-Mola,¹³ Karel Pavelka,¹⁴ Paul P Tak,¹⁵ Desiree van der Heijde,⁶ Ronald F van Vollenhoven,¹⁶ Paul Emery;¹,² for the Rituximab Consensus Expert Committee

ABSTRACT

Background Since initial approval for the treatment of rheumatoid arthritis (RA), rituximab has been evaluated in clinical trials involving various populations with RA. Information has also been gathered from registries. This report therefore updates the 2007 consensus document on the use of rituximab in the treatment of RA.

Methods Preparation of this new document involved many international experts experienced in the treatment of RA. Following a meeting to agree upon the core agenda, a systematic literature review was undertaken to identify all relevant data. Data were then interrogated by a drafting committee, with subsequent review and discussion by a wider expert committee leading to the formulation of an updated consensus statement. These committees also included patients with RA.

Results The new statement covers wide-ranging issues including the use of rituximab in earlier RA and impact on structural progression, and aspects particularly pertinent to rituximab such as co-medication, optimal dosage regimens, repeat treatment cycles and how to manage non-response. Biological therapy following rituximab usage is also addressed, and safety concerns including appropriate screening for hepatitis, immunoglobulin levels and infection risk. This consensus statement will support clinicians and inform patients when using B-cell depletion strategies. New therapeutic strategies and treatment options for RA, a chronic destructive and disabling disease, have expanded over recent years. These have been summarised in general strategic suggestions and specific management recommendations, emphasising the importance of expedient disease-modifying antirheumatic drug implementation and tight disease control. This consensus statement is in line with these fundamental principles of management.

A recent advance in rheumatoid arthritis (RA) has been the introduction of B-cell depletion as a therapeutic modality. Rituximab, a chimeric anti-CD20 monoclonal antibody is the currently available, licensed B-cell depleting agent, with several studies supporting the efficacy and acceptable safety profile of this approach.¹–³ To address the benefits, limitations and safety concerns of its application, a consensus statement on the use of rituximab in patients with RA was formulated in 2006.⁴ Since then a large amount of new information has become available, with new insights into both the efficacy and the safety of B-cell depletion with rituximab.

Therefore, an international group of experts and patient representatives mainly from Europe experienced in clinical research, the use of biological agents and the development of recommendations, convened in Amsterdam in May 2010 to revise the consensus statement. The members of the original expert group were re-invited to participate and, in addition, more recent contributors to the field primarily based on the original publication. The steering group, consisting of MHB, JSS and PE had full control over the invitations. This update will concern the following areas:

- Mode of action
- Indication, considerations and screening for initiating rituximab in RA
- Treatment dose algorithm and co-medication
- Evaluation and management of response as well as lack of response and considerations for retreatment
- Predictive factors of response
- Contraindications and adverse events (AE)
- Long-term exposure—efficacy and safety issues
- Research agenda

Importantly, we have on this occasion placed greater emphasis on the patient perspective.

To achieve our objective, a systematic literature review of the published literature on the efficacy and safety of rituximab in treating patients with RA was first undertaken (MHB) to identify relevant data and information (details included in the supplementary material, available online only).

The outcome of the discussion of the new data and results of this activity will be presented in this publication. Categories of evidence will be indicated next to each reference in line with published guidelines (Table 1);⁵ assignment of the Ia category was agreed to require the availability of two or more randomised controlled trials (RCT) with similar results. Significant amounts of data have been generated and discussed, all of which could not be included within this document but have instead been added in the supplementary material available online only.

MECHANISM OF ACTION OF RITUXIMAB IN RA

Rituximab targets the CD20 molecule, which is expressed on the surface of B cells from pre-B-cell through memory B-cell stages⁶ ⁷ but not on stem
cells and pro B cells nor on plasma cells/blasts. Rituximab leads to transient but almost complete depletion of B cells in the blood and only partial depletion in the bone marrow, and synovial tissue. Response has been shown to correlate with the level of synovial membrane B-cell depletion and early peripheral blood depletion of B cells measured by sensitive assays, possibly useful as a surrogate. It also frequently induces a reduction of immunoglobulins, notably IgM (see supplementary material, available online only, for more detailed discussion).

B-cell repopulation studies following rituximab treatment suggest reconstitution with antigenically inexperienced, transitional B cells derived from an immature population. In some patients, B-cell repopulation leads to a relapse of the disease. However, further investigations to be able to clarify clear patterns predictive of relapse are still needed.

**BACKGROUND**

Rituximab is licensed and well established for patients with non-Hodgkin’s lymphoma. Rituximab has also been approved by the US Food and Drug Administration and by the European Medicines Agency in Europe for the treatment of patients with RA who have had an inadequate response or were intolerant to tumour necrosis factor (TNF) inhibitors. In these patients, according to the licence, rituximab is given intravenously as two 1 g infusions (with intravenous glucocorticoid premedication; table 2), separated by 2 weeks, with concomitant methotrexate. Worldwide, more than 100 000 patients have received rituximab to date for RA.

In earlier studies, rituximab has shown efficacy when used alone (category Ib) and in combination with other agents, including methotrexate (category Ia). The efficacy and durability of monotherapy is less than that of combination treatment with methotrexate (category Ib). Subsequent studies on rituximab in combination with methotrexate have proved to be successful in markedly reducing inflammatory activity and increasing functional ability and quality of life (category Ia). In responding patients, the duration of the response to a single course of rituximab usually lasts more than 6 months (category Ib). Recent phase III studies have also expanded information on the efficacy of rituximab in methotrexate inadequate responders (‘MIRROR’ and ‘SERENE’ studies) and addressed methotrexate-naive patients (‘IMAGE’ study). Response rates in the former studies demonstrated the superiority of rituximab over placebo. In the IMAGE study involving methotrexate-naive patients, rituximab plus methotrexate was superior in clinical and functional outcomes to methotrexate alone; there was also a significant reduction in radiographic progression versus methotrexate monotherapy after 6, 12 and 24 months. Inhibition of structural damage progression had already been shown previously in patients with previous inadequate response to TNF inhibitors treated with methotrexate and rituximab, and this effect was sustained after 2 years (category Ib).

The wider use of rituximab has meant a better appreciation of the associated safety issues with, in particular, focus on infection risk. The oncology literature has highlighted concerns over hepatitis B reactivation. In addition, more specific consequences of B-cell depletion, namely low baseline IgG levels and the observation of subsequent greater infection risk has indicated the value of checking IgG levels before administering rituximab.

In addition to data from clinical trials on the efficacy and safety of rituximab, drug registries may provide information that is complementary to information from the trials. Registries include patients with severe comorbidities that contraindicate the use of, for example, TNF inhibitors, as well as patients treated with rituximab without the previous use of other biological agents and/or receiving rituximab as monotherapy.

**RECOMMENDATIONS**

**Indication**

At present, in line with the current licensed indication, rituximab may be used in adult patients with RA who qualify for treatment with biological agents and have had an inadequate response or intolerance to one or more TNF inhibitors; patients with a contraindication to TNF inhibitors have not yet been adequately studied. However, registry and non-interventional studies have reported 17–20.5% of patients receiving rituximab as their first biological disease-modifying antirheumatic drug (DMARD). Before concluding that a patient has not responded to a TNF inhibitor, attempts should be made to improve the ongoing regimen by optimising the DMARD or TNF inhibitor treatment, considering respective recommendations. The SERENE and MIRROR studies (described later) confirm efficacy in a methotrexate-inadequate responder/TNF inhibitor-naive population and the IMAGE study in methotrexate-naive patients.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Evidence hierarchy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Category of evidence</td>
<td>Type of study</td>
</tr>
<tr>
<td>ia</td>
<td>Meta-analyses of RCT or RCT ≥1 result</td>
</tr>
<tr>
<td>Ib</td>
<td>RCT</td>
</tr>
<tr>
<td>Iia</td>
<td>Controlled study without randomisation</td>
</tr>
<tr>
<td>Iib</td>
<td>Quasi-experimental study</td>
</tr>
<tr>
<td>III</td>
<td>Non-experimental descriptive studies such as comparative, correlation and case–control studies</td>
</tr>
<tr>
<td>IV</td>
<td>Expert committee reports or opinion or clinical experience of respective authorities, or both</td>
</tr>
</tbody>
</table>

Modified from Shekelle et al.

RCT, randomised controlled trial.

| Table 2 | Doses of rituximab and glucocorticoids in six randomised controlled clinical trials |
| --- | --- | --- |
| **Study** | **Rituximab dose** | **Intravenous glucocorticoid** |
| Edwards et al1 (MTX-IR) | 2×1000 mg | 2×100 mg MP on days 1 and 15 |
| Emery et al2 (DANCER) (MTX+TNF-IR) | 2×1000 mg or 2×500 mg | (1) 0 |
| Cohen et al3 (REFLEX) (TNF-IR) | 2×1000 mg | (2) 2×100 mg MP |
| Tak et al4 (IMAGE) (MTX-naive) | 2×1000 mg or 2×500 mg | (3) 2×100 mg MP |
| Rubbert-Roth et al5 (MIRROR) (MTX-IR) | 2×1000 mg or 2×500 mg or 1×1000 mg and 1×500 mg | 2×100 mg MP |
| Emery et al6 (SERENE) (MTX-IR) | 2×1000 mg or 2×500 mg | 2×100 mg MP |

No marked difference in efficacy between the two rituximab doses. IMAGE: 2×1000 mg associated with structural retardation first 24 weeks; maintenance with both rituximab doses week 24 to 2 years. Premedication associated with reduced infusion-related events infusion one; minimal difference for infusion two. IR, inadequate-responder; MP, methylprednisolone; MTX, methotrexate; P, prednisolone; TNF, tumour necrosis factor.
Current evidence on the efficacy of rituximab relates primarily to rheumatoid factor (RF) positive patients. While in the phase III (REFLEX) study on TNF inhibitor non-responders, a response was seen in RF-negative patients, other sub-study analyses on RF-negative patients showed that the response in this population was not significantly different from placebo-treated patients. Indeed, in the first of these studies (REFLEX), protection from joint damage was only evident in seropositive patients.

Recently, pooled data from two phase III studies in methotrexate-inadequate responder populations as well as a sub-study from the IMAGE study that evaluated methotrexate-naive patients have all reinforced the view that seropositive patients (anti-citrullinated peptide antibody (ACPAs), RF or both) demonstrate a more robust response to rituximab (table 3; data discussed in the supplementary material available online only). In the IMAGE study, there was evidence of significantly greater joint protection in the seropositive subpopulation treated with rituximab and methotrexate; while in the seronegative group, inhibition of progression of damage in each treatment group was comparable and generally low even in the placebo/methotrexate group. Superior efficacy has also been demonstrated in drug registries for patients who were RF and/or ACPA positive with compared when with the seronegative patient group. Another study (discussed further in the supplementary material available online only) identified the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SERENE study; the four best potential biomarkers from the REFLEX study (that included IgA RF and IgG anti-CCP3) and applied these, together with IgM and IgG isotypes of RF to the SEREN...
approach with a call for revision of ACR guidelines with, in addition, a recent publication of a provisional clinical opinion from the American Society of Clinical Oncology.\textsuperscript{28-30}

Chest radiography was also carried out in the clinical trials. Patients who did not respond to TNF inhibitor treatment will also have been prescreened for the presence of active or latent tuberculosis. In the RA clinical trials on rituximab before TNF inhibitor, patients with active tuberculosis were excluded, but patients were not screened for latent tuberculosis by any testing. The fact that rituximab is administered in RA with two pulses of glucocorticoid may by itself contribute to the risk of reactivation of tuberculosis. \textsuperscript{61} However, there is no evidence of an increased frequency of tuberculosis in patients with lymphoma treated with rituximab\textsuperscript{62} and, therefore, at this time there is no evidence indicating the necessity to screen patients systematically for tuberculosis before using rituximab in those with RA.

Apart from routine laboratory tests usually performed in patients with RA before initiating new treatments, baseline IgG levels should be determined, as a reduced baseline level of IgG is a risk factor for severe infections with rituximab;\textsuperscript{30} in addition, a recent publication of a provisional clinical opinion on vaccination provide additional guidance for patients with rheumatological diseases treated with biological agents.\textsuperscript{25}

Vaccination

Some data from the oncology literature indicate that in patients receiving rituximab, response to vaccination may be ineffective.\textsuperscript{62} Patients with RA receiving rituximab have been investigated for their response to vaccination in two studies, one of which was a RCT\textsuperscript{63} (discussed in the supplementary material, available online only). Any patient considered for rituximab therapy should receive all indicated vaccines (hepatitis B for at-risk population, pneumococcus, tetanus toxoid every 10 years, influenza annually) before treatment. Ideally, vaccination should be undertaken at least 4 weeks before rituximab therapy. More data are needed on the potential risk of vaccination with live vaccines, which are therefore not recommended for rituximab-treated patients.

European League Against Rheumatism (EULAR) recommendations on vaccination provide additional guidance for patients with rheumatological diseases treated with biological agents.\textsuperscript{25}

Treatment dose and co-medication

Treatment dosage

In patients who have received previous TNF inhibitor treatment, rituximab use is licensed at a dose of 1000 mg per infusion on days 1 and 15.\textsuperscript{2} Rituximab showed significant efficacy

### Table 4 Summary of response rates in the six key randomised controlled studies evaluating rituximab and methotrexate

<table>
<thead>
<tr>
<th>Study</th>
<th>Response measure</th>
<th>6 Months</th>
<th>12 Months</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Plc + MTX</td>
<td>RTX (2×500 mg) + MTX</td>
</tr>
<tr>
<td>MTX-naive</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IMAGE\textsuperscript{25} (n=755)</td>
<td>ACR 20</td>
<td>64.3</td>
<td>76.7</td>
</tr>
<tr>
<td></td>
<td>ACR 50</td>
<td>41.8</td>
<td>59.4</td>
</tr>
<tr>
<td></td>
<td>ACR 70</td>
<td>24.9</td>
<td>42.2</td>
</tr>
<tr>
<td></td>
<td>EULAR (mod+good)</td>
<td>71.1</td>
<td>82.3</td>
</tr>
<tr>
<td></td>
<td>DAS29 Rem</td>
<td>12.6</td>
<td>25.4</td>
</tr>
<tr>
<td>MTX-IR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase IIa\textsuperscript{2} (n=80)</td>
<td>ACR 20</td>
<td>38.0</td>
<td>73.0</td>
</tr>
<tr>
<td></td>
<td>ACR 50</td>
<td>13.0</td>
<td>43.0</td>
</tr>
<tr>
<td></td>
<td>ACR 70</td>
<td>5.0</td>
<td>23.0</td>
</tr>
<tr>
<td></td>
<td>EULAR (mod+good)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>DAS29 Rem</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SERENE\textsuperscript{24} (n=512)</td>
<td>ACR 20</td>
<td>23.3</td>
<td>54.5</td>
</tr>
<tr>
<td></td>
<td>ACR 50</td>
<td>9.3</td>
<td>26.3</td>
</tr>
<tr>
<td></td>
<td>ACR 70</td>
<td>5.2</td>
<td>9.0</td>
</tr>
<tr>
<td></td>
<td>EULAR (mod+good)</td>
<td>50.0</td>
<td>82.0</td>
</tr>
<tr>
<td></td>
<td>DAS29 Rem</td>
<td>4.0</td>
<td>16.0</td>
</tr>
<tr>
<td>MIRROR\textsuperscript{22} (n=227; excludes dose escalation group)</td>
<td>ACR 20</td>
<td>64.0</td>
<td>72.0</td>
</tr>
<tr>
<td></td>
<td>ACR 50</td>
<td>39.0</td>
<td>48.0</td>
</tr>
<tr>
<td></td>
<td>ACR 70</td>
<td>20.0</td>
<td>23.0</td>
</tr>
<tr>
<td></td>
<td>EULAR (mod+good)</td>
<td>73.0</td>
<td>89.0</td>
</tr>
<tr>
<td></td>
<td>DAS29 Rem</td>
<td>9.0</td>
<td>19.0</td>
</tr>
<tr>
<td>MTX±TNF-IR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DANCER\textsuperscript{21} (n=465)</td>
<td>ACR 20</td>
<td>28.0</td>
<td>55.0</td>
</tr>
<tr>
<td></td>
<td>ACR 50</td>
<td>13.0</td>
<td>33.0</td>
</tr>
<tr>
<td></td>
<td>ACR 70</td>
<td>5.0</td>
<td>13.0</td>
</tr>
<tr>
<td></td>
<td>EULAR (mod+good)</td>
<td>37.0</td>
<td>73.0</td>
</tr>
<tr>
<td></td>
<td>DAS29 Rem</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNF-IR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>REFLEX\textsuperscript{3}</td>
<td>ACR 20</td>
<td>18.0</td>
<td>51.0</td>
</tr>
<tr>
<td></td>
<td>ACR 50</td>
<td>5.0</td>
<td>27.0</td>
</tr>
<tr>
<td></td>
<td>ACR 70</td>
<td>1.0</td>
<td>12.0</td>
</tr>
<tr>
<td></td>
<td>EULAR (mod+good)</td>
<td>20.0</td>
<td>50.0</td>
</tr>
<tr>
<td></td>
<td>DAS29 Rem</td>
<td>0</td>
<td>9.0</td>
</tr>
</tbody>
</table>

*ACR, American College of Rheumatology; DAS28, disease activity score 28; EULAR, European League Against Rheumatism; IR, inadequate-responder; mod, moderate; MTX, methotrexate; Plc, placebo; Rem, remission; RTX, rituximab; TNF, tumour necrosis factor.*
on signs and symptoms as well as physical function in this population. The effect on structural damage was also evaluated in that trial (REFLEX), in which the 2 × 1000 mg dose was studied. Radiographic benefit compared with placebo was demonstrated at 1 year26 (but not at 24 weeks), 3 26 with recent data confirming maintenance of retardation at 2 years.27

Subsequent studies in all other RA populations, namely patients with previous inadequate response to traditional DMARD including methotrexate and patients naive to methotrexate, have also evaluated a lower dose of 500 mg per infusion.2 23–25

The SERENE24 and MIRROR25 studies both addressed methotrexate-inadequate responder patients and included two courses of 2 × 500 and 2 × 1000 mg 6 months apart; SERENE also had a placebo arm for comparison, while MIRROR adopted an additional dose escalation regimen—one course of 2 × 500 mg followed by a course of 2 × 1000 mg. ACR20, ACR50 and ACR70 response rates in patients treated with these rituximab doses were similar (as detailed in table 4 and discussed further in the supplementary material, available online only) (category Ib). Effects on joint damage were not assessed in this study.

In the IMAGE study in methotrexate-naive patients, the 2 × 500 and 2 × 1000 mg dose groups were again compared.25 The clinical and functional outcomes were very similar. The higher dose (2 × 1000 mg) cohort demonstrated significantly superior joint protection compared with placebo, while the lower dose (2 × 500 mg) had numerical, although not statistical, radiographic benefit during the first 24 weeks. Beyond this time point, however, (study duration of 2 years) radiographic progression was minimal and indeed similar in both dose groups. These results are illustrated in the supplementary section available online only.

These data are important in expanding upon those observed in the previous TNF inhibitor-experienced population from the REFLEX study described above. The optimal dose of rituximab thus remains insufficiently defined, with considerable data suggesting an overall equivalence of 2 × 500 mg with the licensed dose of 2 × 1000 mg for clinical efficacy outcomes and medium-term maintenance of radiographic non-progression. More research is required in this area.

In the phase II trial, the ACR responses of patients treated with rituximab in combination with methotrexate were numerically superior to those receiving monotherapy (table ).2 Rituximab monotherapy was also shown to be more effective than placebo only in ACR20 response but not in ACR50 and ACR70 responses2 (category Ib). Rituximab is therefore only licensed in combination with methotrexate (www.accessdata.fda.gov/scripts/cder/drugsatfda, www.ema.eu.int/humans/Humans/EPAF/mabthera/mabthera). In clinical practice this will usually be a dose of 0–25 mg methotrexate per week, unless intolerance precludes such doses (category Ib).

Other combinations

A number of abstracts (small observational studies and registry data) have described the use of rituximab with DMARD other than methotrexate31 66 (category III). They consistently demonstrate that leflunomide can be used safely and effectively as background DMARD therapy. The observational study, SUNDIAL, demonstrated the safety of rituximab on a variety of background non-biological DMARD and combinations30 (category III). An initial, relatively small randomised study (TAME) assessed rituximab on background etanercept or adalimumab and showed more infections with this combination67 (category IIa); this approach should therefore be avoided. Data are available from the phase II trials on cyclophosphamide as co-medication, although given the availability of safer and more effective alternatives, in patients with RA at least, this expert group felt that cyclophosphamide is unnecessary as a co-medication.

Rituximab administration and glucocorticoid premedication

To reduce the frequency and severity of infusion reactions, patients should receive 100 mg methylprednisolone intravenously before rituximab infusions (category Ib). This is particularly indicated before the first infusion and can also be given before the second infusion of each cycle, although the indication may not be as strong for the latter.2 68 Paracetamol and antihistamines may be required, and although they have been used for premedication in all clinical trials on RA, there is no clear evidence from these that antihistamines should be used systemically.

Evaluation and management of response/non-response

Response assessment

Routine rheumatological assessments should be performed at baseline and periodically according to standards of care for therapies with biological agents and methotrexate. Response to rituximab should be assessed by validated composite measures of disease activity (eg, the DAS28, SDAI or CDAI);69 Functional assessment (health assessment questionnaire), and evaluation of radiographic progression further complement the use of these scores. At least a low disease activity range (DAS28 ≤3.2, SDAI ≤11 or CDAI ≤10) and a maximisation of functional ability and quality of life should be the target to aim for with regard to a desirable disease state.49

Response profile

Rituximab has a more distinctive response profile in that the onset of action of rituximab is slower than that of the other biological DMARD. Furthermore, it should be noted that intravenous glucocorticoid premedication will produce an early, albeit a usually transient, response before 8 weeks. It is important that this is communicated to the patient. A patient should be regarded as a responder if the response criteria are met after an observation period of at least 16 weeks from the initiation of treatment according to the recommended dosing schedule. Indeed, in most patients, a response (ie, some degree of improvement in disease activity) is usually seen by 16 weeks after the first infusion1–3 (category Ia). Rituximab usually leads to rapid B-cell depletion1–3 (category Ia).

Considerations for repeated treatment

Repeated treatment should be considered after at least 24 weeks (category IV). In line with the ‘treat-to-target’ and EULAR RA management recommendations,66 67 this should be considered in patients who do not reach remission (exhibiting a DAS28 ≥2.6, SDAI >3.8 or CDAI ≥2.8)67 or at least low disease activity (although with consideration of alternative targets if individual factors make it unlikely that either of these are achievable).46

It is worth noting that the earliest retreatment was undertaken after 4 months.3

Notwithstanding the above, the optimal treatment paradigm for rituximab has not been definitively determined. Options include treatment on flare as practised in earlier RCT, regular re-treatment, for example, every 6 months, treatment with any deterioration or treatment-to-target. This is discussed in more detail in the supplementary material, available online only, with data from pooled phase II and III studies69 as well as preliminary data from the German registry.70 Retrospective data support in principle a treatment-to-target strategy, whereas regular re-treatment may risk overtreatment in some patients. Of note, a lack...
of long-term safety data relating to different dosing regimens in the re-treatment of RA means it is important that caution is exercised if or when patients are being regularly re-treated.

Managing non-response
Several studies have reported the outcome of re-treating rituximab non-responders with a further cycle. Several of these (with, in one study, 95% of non-responders showing poor early peripheral blood B-cell depletion using a high sensitivity assay) demonstrate that seropositive patients who fail to respond to a first course of rituximab may respond to a second course (accompanied by more complete B-cell depletion). A couple of other studies, however, suggest little improvement to be gained with re-treatment. In light of the availability of other therapeutic options, for individual (particularly seronegative) patients who are rituximab non-responders or insufficient responders, other treatment options should be considered depending on previous drug history.

Post-TNF inhibitor failure and biological DMARD therapy after rituximab

Post-TNF inhibitor failure
A few observational, registry-based and single-centre studies have compared the use of rituximab in TNF inhibitor inadequate responders versus switching to another TNF inhibitor (discussed in the supplementary material, available online only). There has been no head-to-head comparison to date, with a recent meta-analysis confirming similar clinical benefits from these RCT. Associated management recommendations did not establish a preference for a particular biological agent in this situation.

Safety of other biological DMARD post-rituximab
Switching from rituximab to a TNF inhibitor has been associated with a numerically, but not statistically, significant increase in serious infections in an early study; a subsequent report providing further follow-up of the same cohort did not suggest a major increase in infections under these circumstances. In this latter report TNF inhibitors were usually initiated at least 4 months after rituximab (when insufficient treatment response would be judged). No significant increase in serious infections was noted compared with the incidence before the new biological DMARD (TNF inhibitors in the majority of cases), with similar rates to a biological DMARD-naive group commenced on a TNF inhibitor; however, a wide interval from rituximab exposure to subsequent biological DMARD exposure was present (0.5–37 months) with a small sample size. Data from the French Autoimmunity and Rituximab and Orencia in Rheumatoid Arthritis registries indicate that previous use of rituximab followed by treatment with abatacept does not increase the short-term risk of severe infection. These are preliminary reports and clearly further data on the safety of using other biological DMARD before or after rituximab need to be established.

Cost-effectiveness
Rituximab has been evaluated as a cost-effective treatment with three studies comparing rituximab with TNF inhibitor following TNF inhibitor failure; the methods differed slightly but all suggested equivalent/favourable results towards rituximab.

Role of rituximab in other autoimmune diseases
In addition to RA, accumulating evidence suggests rituximab could also be an effective treatment option in the management of patients with vasculitis, connective tissue diseases and other autoimmune conditions. Data that have emerged from recent RCT are summarised in the supplementary material available online only.

CONTRAINDICATIONS AND AE

Contraindications
Contraindications to rituximab include hypersensitivity to rituximab or other murine proteins, active severe infections and severe heart failure (New York Heart Association class IV; www.accessdata.fda.gov/scripts/cder/drugsatfda, www.ema.eu.int/humans/Humans/EPAR/mabthera/mabthera). In non-Hodgkin’s lymphoma, contraindications have been restricted to hypersensitivity to components of this product or murine proteins. Patients with active infections (acute or chronic) should not be treated with rituximab.

Use in children
Safety and efficacy in children with rheumatic diseases has not been established although an increasing number of case reports and series of successful rituximab usage are available in the literature.

Pregnancy
Rituximab treatment during pregnancy is contraindicated. A recent review of pregnancy outcomes from the rituximab global drug safety database identified 231 cases of pregnancy associated with maternal rituximab exposure. Of 153 pregnancies with known outcomes, 90 resulted in live births, 33 ended in spontaneous abortion, with one stillbirth at 20 weeks’ gestation (umbilical knot) and 28 elective terminations. Twenty-two of the live births were premature, with one neonatal death at 6 weeks. Eleven infants had haematological abnormalities at birth; four neonatal infections and two congenital malformations were reported. A recent review of RA medications in pregnancy included B-cell levels during eight of these cases of rituximab exposure during pregnancy; two cases were during the first trimester and were not associated with any B-cell depletion in the fetus; six cases in the second or third trimesters included three with similar rituximab levels to the mother with markedly reduced/undetectable B-cell numbers—spontaneous recovery was, however, observed within 6 months. IgG levels were tested and were normal in four out of the six cases and vaccination responses remained intact. The appropriate time interval between the last rituximab treatment and subsequent conception remains unclear. Although additional data are now becoming available, further data are required before safety recommendations for pregnancy can be produced; until that time contraception is recommended for 12 months after the last rituximab application in the label, and rituximab should also be avoided in lactating women (www.accessdata.fda.gov/scripts/cder/drugsatfda, www.ema.eu.int/humans/Humans/EPAR/mabthera/mabthera).

Adverse events
Table 5 lists the more frequent (≥2%) AE recorded during the 6-month placebo-controlled period from nine studies (IIa, IIb (DANCER), DANCER extension, REFLEX (and REFLEX extension), SERENE, MIRROR, SUNRISE and SIERRA studies); data for the placebo and methotrexate group have been pooled from the first phase IIa, IIb (DANCER), REFLEX and SERENE studies.

Infusion-related reactions
The tolerability and safety of rituximab has been well described in clinical trials on patients with RA and review articles on
non-Hodgkin’s lymphoma (category III)^1 2 18 (category Ia). The most frequent AE are infusion reactions (30–35% with the first infusion with concomitant glucocorticoids). Fewer reactions are observed with the second and subsequent infusions^1–3 18 (category Ia). They are usually mild to moderate, but may require therapeutic intervention (additional paracetamol, antihistamines, bronchodilators, eventually glucocorticoids). Severe infusion reactions leading to drug discontinuation are uncommon (<1%) and are mainly restricted to the first infusion (Roche data on file). Their frequency is reduced by the use of concomitant intravenous steroids^1–3 (category Ia; www.accessdata.fda.gov/scripts/cder/drugsatfda , www.ema.eu.int/humans/Humans/EPAR/mabthera/mabthera ).^33 There have been several reports from haematology experience on the safety of shortened (60–90 min) infusion times.95–99

In the context of glucocorticoid use with rituximab, AE due to glucocorticoids also need to be considered.

### Serious infections

Rituximab does not seem to increase the risk of infections in patients with HIV with lymphoma^62 100 (category IIb). In the oncology literature, rituximab does not markedly add to the risk of infections induced by chemotherapy; this includes opportunistic infections^62 and also herpes zoster infections, although there was one case of disseminated and fatal herpes zoster infection.62 101 In the long-term safety analysis of RA trials^10 11 herpes zoster occurred in 2% of patients (n=49; 0.98 events/100 patient-years) with only one case a serious AE; this rate appears to be similar to the rate seen with TNF inhibitors (1.11 events/100 patient-years).102

In two clinical trials carried out on patients with RA,2 3 a numerically higher rate of serious infections (but not opportunistic infections, including tuberculosis) was seen in patients receiving rituximab at 2×1000 mg compared with those receiving placebo: 4.7 versus 3.2/100 patient-years in the DANCER study and 5.2 versus 3.7/100 patient-years in the REFLEX study^2 3 (category III). In the recent IMAGE study in methotrexate-naive patients, however, serious infections were lower in the two rituximab dosage groups (1000 and 500 mg) compared with placebo (3.74, 4.61 and 6.09 events/100 patient-years, respectively).25 A recent meta-analysis included three

### Table 5  AE occurring during the 6-month placebo-controlled period of nine studies^18

<table>
<thead>
<tr>
<th>Total patients (%) with ≥1 AE infection</th>
<th>Placebo + MTX</th>
<th>Rituximab + MTX</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nasopharyngitis</td>
<td>43 (7.5)</td>
<td>63 (7.2)</td>
</tr>
<tr>
<td>Upper respiratory tract infections*</td>
<td>37 (6.5)</td>
<td>64 (7.3)</td>
</tr>
<tr>
<td>Urinary tract infection*</td>
<td>31 (5.4)</td>
<td>31 (5.5)</td>
</tr>
<tr>
<td>Bronchitis*</td>
<td>19 (3.3)</td>
<td>27 (3.1)</td>
</tr>
<tr>
<td>Sinusitis</td>
<td>20 (3.5)</td>
<td>25 (2.9)</td>
</tr>
<tr>
<td>Gastroenteritis</td>
<td>14 (2.5)</td>
<td>12 (1.4)</td>
</tr>
<tr>
<td>Pharyngitis</td>
<td>12 (2.1)</td>
<td>11 (1.3)</td>
</tr>
<tr>
<td>Total patients (%) with a serious infection</td>
<td>9 (1.6)</td>
<td>15 (1.7)</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>2 (0.4)</td>
<td>2 (0.2)</td>
</tr>
<tr>
<td>Gastroenteritis</td>
<td>2 (0.4)</td>
<td>1 (0.1)</td>
</tr>
<tr>
<td>Pyelonephritis</td>
<td>0</td>
<td>3 (0.3)</td>
</tr>
<tr>
<td>Respiratory tract infection</td>
<td>2 (0.4)</td>
<td>0</td>
</tr>
<tr>
<td>Abscess bacterial</td>
<td>1 (0.2)</td>
<td>0</td>
</tr>
<tr>
<td>Abscess intestinal</td>
<td>1 (0.2)</td>
<td>0</td>
</tr>
<tr>
<td>Bronchitis</td>
<td>0</td>
<td>1 (0.1)</td>
</tr>
<tr>
<td>Bronchopneumonia</td>
<td>1 (0.2)</td>
<td>0</td>
</tr>
<tr>
<td>Cellulitis</td>
<td>0</td>
<td>1 (0.1)</td>
</tr>
<tr>
<td>Cellulitis gangrenous</td>
<td>0</td>
<td>1 (0.1)</td>
</tr>
</tbody>
</table>

Infusion-related reactions were the most common adverse event (AE) (25% infusion 1). Data for the placebo + methotrexate (MTX) group pooled from trials IIa, DANCER, REFLEX and SERENE. The overall rate (95% CI) of AE was 359.6 events per 100 patient-years (354.4 to 364.9) with highest rates during course 1; for serious AE, the rate (95% CI) was 17.85 events per 100 patient-years (16.72 to 19.06).^* Occurred in ≥10% patients.

### Table 6  Summary of additional clinical and research aspects for future consideration

<table>
<thead>
<tr>
<th>Future clinical and research agenda</th>
<th>Rituximab in the context of concomitant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safety</td>
<td>Milder congestive heart failure (NYHA I–II)</td>
</tr>
<tr>
<td></td>
<td>Demyelinating disorders (efficacy seen in phase I–II studies of MS/NMO)</td>
</tr>
<tr>
<td></td>
<td>New-onset malignancy</td>
</tr>
<tr>
<td>Registry data</td>
<td>Tuberculosis reactivation</td>
</tr>
<tr>
<td>Rare serious AE (PML)</td>
<td>Parameters associated with infection risk (Ig)</td>
</tr>
<tr>
<td>Vaccination—minimal interval between vaccine and RTX administration</td>
<td></td>
</tr>
</tbody>
</table>

### Efficacy

<table>
<thead>
<tr>
<th>Disease groups</th>
<th>Connective tissue disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>RA/vasculitis; overlap syndromes</td>
<td></td>
</tr>
</tbody>
</table>

### Dosage regimen

<table>
<thead>
<tr>
<th>Different induction and maintenance regimens?</th>
<th>Impact of different dosage regimens on structural progression</th>
</tr>
</thead>
</table>

### Concomitant medication

| Alternative DMARD to MTX | Timing and initiation of DMARD | Combination RTX with other biological agent |

### Flare and retreatment

| Early signs of flare/reactivation | Long-term impact of re-treatment/repeat multiple cycles |

### Translational research

| Mechanism of action of RTX | Biomarkers of response | Indicators of re-treatment (B cell/subsets) |

### Switching biological therapies

| Merit of RTX following initial TNF-i failure compared to alternative TNF-i or other biological agent | |

### Pharmacoeconomic analyses

| DMARD, disease-modifying antirheumatic drug; MS, multiple sclerosis; MTX, methotrexate; NMD, neuromyelitis optica; NYHA, New York Heart Association; PML, progressive multifocal leukoencephalopathy; RA, rheumatoid arthritis; RTX, rituximab; TB, tuberculosis; TNF-i, tumour necrosis factor inhibitor. |
### Box 1 Points to consider for treatment with rituximab

**Indication**
- RA with inadequate response to (or intolerance of) TNF inhibitors
- Active RA (at least moderate disease activity)
- Possibly: RA with contraindication to TNF inhibitors (especially lymphoma) and inadequate response to disease-modifying antirheumatic drugs such as methotrexate, particularly given new data on methotrexate-inadequate responder and naive patient groups

**Contraindications**
- Allergy to rituximab
- Clinically relevant comorbidities, including active infections and severe heart failure (New York Heart Association class IV)
- Pregnancy

**Pretreatment screening**
- History and physical examination
- Consider possible contraindications
- Consider radiograph of the chest
- Routine laboratory testing
- Immunoglobulin levels
- Testing for hepatitis B; consider testing for hepatitis C
- Assess necessity of vaccination

**Treatment dose and co-medication**
- Two 1000 mg intravenous infusions separated by 2 weeks (licensed regimen in TNF inhibitor failures)
- Two 500 mg intravenous infusions separated by 2 weeks have similar clinical, functional and long-term radiographic efficacy (studied in all populations except TNF inhibitor failures)
- 100 mg intravenous methylprednisolone or equivalent before infusions
- Weekly methotrexate to increase efficacy (if tolerated)
- Other DMARD (especially leflunomide) may be used as an alternative

**Evaluation and definition of response**
- Validated composite indices to assess response
- Minimum improvement of DAS28 of 1.2 or greater or equivalent measure
  - Aim for remission (DAS28 <2.6, SDAI ≤3.3 or CDAI ≤2.8) or low disease activity state (DAS28 ≤3.2, simplified disease activity index (SDAI) ≤11, clinical disease activity index (CDAI) ≤10)
- Aim for improvement in function and quality of life; minimum response is usually achieved in 16 weeks

**Repeated treatment**
- Should be considered in responders after week 16
  - Residual active disease (at least low disease activity state, ie, DAS28 ≥2.6, SDAI >3.3, CDAI >2.8)
  - Reactivation of disease from low disease activity state (increase in DAS28 of >0.6 or equivalent)

**Adverse events**
- Infusion reactions (30–35% after the first infusion; less with the second infusion)
- Severe infusion reactions may occur but are rare
- Slight increase in infections compared with placebo population, especially in patients with low IgG
- Cases of PML have been reported (~1:20 000)

---

RCT and did not observe an increased risk of severe infections in RA patients treated with rituximab compared with placebo. Registry data have suggested that serious infections tend to occur in the initial months following rituximab, with predisposing factors comprising age, comorbidity, extra-articular involvement and low IgG.

Hepatitis B reactivation has been widely documented in the oncology literature highlighting the need to pre-screen patients (see the earlier section on ‘Screening before initiating rituximab’ with additional information provided in the supplementary material, available online only). Clinical trials in RA pre-screened patients for hepatitis B and C. Only one case of hepatitis B reactivation in a patient with RA has been reported. Although the risk of hepatitis C virus is not as clear we would also recommend pre-screening. Management in consultation with an expert gastroenterologist/hepatologist is advised.

In the clinical trial safety database, two cases of pulmonary tuberculosis have been reported; these appear to have been de novo infections (information from Roche). Among patients with RA, three cases of tuberculosis and five cases with non-tuberculous mycobacterial infections have been reported through a survey carried out in the USA and Canada. However, patients with records of tuberculosis have been treated with rituximab without any tuberculosis reactivation.

In RA, six cases with progressive multifocal leukoencephalopathy (PML) have been reported (Roche data on file), including one case from the REFLEX trial giving an incidence of less than 1:20 000 treated RA patients, compared with PML risks for patients with psoriasis treated with efalizumab (1:400) and patients with Crohn’s disease and multiple sclerosis treated with natalizumab (1:1000). Most PML cases with RA had longstanding disease with numerous previous immunosuppressive treatments; only one patient had early RA naive to methotrexate and other DMARD. Currently, there is no identified risk profile for developing PML. Although the risk seems small, at this stage we would still advise clinicians to maintain vigilance. Additional background information on PML is provided in the supplementary material, available online only.
Immunoglobulin levels and infection risk

The literature on patients with RA treated with rituximab describes low baseline levels of IgG, including before rituximab administration, as being associated with an increased risk of serious infections—these data come from a registry (hypo-IgG being present at baseline before rituximab in 5% of patients) as well as from compiled data from clinical trials. In open extension studies, the occurrence of IgG levels below the lower limit of normal under rituximab treatment, especially sustained (≥4 month) IgG below the lower limit, was associated with an increased risk of serious infections (data provided by Roche). In general, in addition to more traditional risk factors for infection such as age and concomitant glucocorticoid, patients with low IgG levels particularly need careful observation. Better definition and clarity on the management of low IgG is still needed; nevertheless, from the data summarised to date, as recommended earlier, IgG should be monitored in patients treated with rituximab, particularly in those who demonstrate low baseline levels, with close monitoring particularly in higher-risk patient groups such as the older patient. The more frequent decreases in IgM, in contrast, have not been associated with increased rates of infections. After 1 year of treatment, levels of IgM were lower in patients receiving 2×1000 mg versus those receiving 2×500 mg (unpublished Roche data).

Malignancy risk

Although patients with previous malignancy are usually excluded in clinical trials; so far, no enhanced rates of solid malignancies or lymphoma under rituximab treatment have been observed (category Ia) with the exception of individuals with T-cell deficiency in HIV infection (category III). Therefore, to date, there have been no safety signals regarding malignancies; however, with respect to RA, larger databases on safety data are required before any firm conclusions can be drawn.

Haematological side-effects

In the oncology literature, late-onset neutropenia has been reported in up to 8% of patients treated with rituximab monotherapy and combination treatment and may occur up to 1 year after treatment (category Ia) (category III). For unknown reasons, this complication is very rare in patients treated for autoimmune diseases. In some patients treatment with granulocyte colony-stimulating factor has been required. A multifactorial aetiology is likely to underlie the blood dyscrasia.

Human antichimeric antibodies

As rituximab is a chimeric antibody, human antichimeric antibodies (HACA) may occur. In the long-term, pooled safety analysis, 11% (273/2576 patients) were HACA positive on at least one visit. The rate of infusion reaction with re-treatment was similar in the HACA-positive compared with HACA-negative patients. AE related to HACA are rare, but a case of a severe allergic reaction was reported in which HACA apparently prevented B-cell depletion (category IV) (www.accessdata.fda.gov/scripts/cder/drugsatfda.www.epa.eu.int/humans/Humans/EPAR/mabthera/mabthera). The development of HACA does not appear to influence the clinical efficacy of rituximab treatment.

Long-term safety of rituximab

A recent pooled analysis of safety data from the rituximab in combination with methotrexate global clinical trial programme were based on 5013 patient-years of rituximab exposure (n=2576 having received at least one course of rituximab). The rate of AE and serious events including infections and serious infections remained stable across several courses.

ADDITIONAL ASPECTS TO BE CONSIDERED AND RESEARCH AGENDA

It is evident from this document that several areas of future investigation and research are warranted. These are summarised in table 6 but are discussed in detail in the supplementary material, available online only. These relate particularly to mode of action, safety and efficacy issues; with respect to the latter, questions such as optimal dose regimen, direct comparison with other biological agents and indicators for retreatment require appropriate answers.

CONCLUSION

Additional data on rituximab in the management of RA have accumulated since publication of the first consensus statement and have provided further insights into its use (box 1). Benefit in earlier disease has been demonstrated together with novel radiographic information. It is now also firmly established that rituximab is effective primarily in seropositive RA. Recent studies have further supported the efficacy of reduced dosage and different regimens, although more work is needed to establish the optimal strategy. Safety data from rheumatology as well as oncology literature highlight the need for hepatitis screening as well as checking pretreatment immunoglobulin levels to identify patients possibly at greater risk of infection. Data thus far do not indicate the need for routine tuberculin screening. As with other biological agents, the need for vaccination should be assessed. Safety concerns for very rare events such as PML have emerged. Ongoing evaluations should clarify the remaining open issues and ultimately lead to a more refined application of rituximab therapy.

Author affiliations

1Section of Musculoskeletal Diseases, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK
2NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK
3Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
4Center for Rheumatic Diseases, Hietzing Hospital, Vienna, Austria
5Arthritis Care, UK
6Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
7Department of Rheumatology and Clinical Immunology, Humboldt University, Charité Berlin, Germany
8Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy
9Rheumatology Department, Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France
10Institute of Cellular Medicine, Newcastle University Medical School, Newcastle upon Tyne, UK
11Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
12Institut Pour la Santé et la Recherche Médicale (INSERM) U 1012, Hôpital Bicêtre, Université Paris-Sud 11, Paris, France
13La Paz Hospital, Madrid, Spain
14Institute of Rheumatology and Clinic of Rheumatology Charles University, Prague, Czech Republic
15Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands
16Rheumatology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Solna, Sweden

Rituximab Consensus Expert Committee

Jordi Carbonell Abelló (Spain), Marwan Bukhari (UK), Harald Burkhardt (Germany), Bernard Combe (France), Juan-Jesus Gomez-Reino Carnota (Spain), Leonor Baril Fabris (Mexico), Lars Klareskog (Sweden), Jose Luis Menecro de la Fuente (Spain), Carlo-Maurizio Montecucco (Italy), Mikkel Ostergaard (Denmark), Eliseo Pascual Gomez (Spain), Raimon Sanmarti Sala (Spain), Hans-Peter Tony (Germany), Guido Valesini (Italy), Jaap van Laar (UK), Piet van Riel (The Netherlands).
including the final recommendations were not influenced by the sponsor and no representative of the sponsor was present in any of the discussion sessions.

Competing interests All participants except the patient representative have been active on advisory boards or participated in clinical trials by the sponsor. Professor Johannes Bijlsma was the handling editor.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES


Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

Maya H Buch, Josef S Smolen, Neil Betteridge, et al.

*Ann Rheum Dis* 2011 70: 909-920 originally published online March 6, 2011
doi: 10.1136/ard.2010.144998

Updated information and services can be found at:
http://ard.bmj.com/content/70/6/909.full.html

These include:

**Data Supplement**
"Web Only Data"
http://ard.bmj.com/content/suppl/2011/01/12/ard.2010.144998.DC1.html

**References**
This article cites 109 articles, 45 of which can be accessed free at:
http://ard.bmj.com/content/70/6/909.full.html#ref-list-1

Article cited in:
http://ard.bmj.com/content/70/6/909.full.html#related-urls

**Open Access**
This paper is freely available online under the BMJ Journals unlocked scheme, see http://ard.bmj.com/info/unlocked.dtl

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Open access (249 articles)
- Connective tissue disease (2828 articles)
- Degenerative joint disease (3082 articles)
- Immunology (including allergy) (3324 articles)
- Musculoskeletal syndromes (3316 articles)
- Rheumatoid arthritis (2129 articles)
- Epidemiology (940 articles)
- Travel medicine (29 articles)

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/